TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 91 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q2 2017. The put-call ratio across all filers is 2.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $134,000 | -80.6% | 100,000 | -60.0% | 0.00% | -100.0% |
| Q3 2018 | $690,000 | +285.5% | 250,000 | +400.0% | 0.00% | – |
| Q2 2018 | $179,000 | -98.9% | 50,000 | -98.0% | 0.00% | -100.0% |
| Q4 2017 | $16,091,000 | -7.9% | 2,554,100 | 0.0% | 0.03% | -16.7% |
| Q3 2017 | $17,470,000 | +48.1% | 2,554,100 | +54.4% | 0.04% | +33.3% |
| Q2 2017 | $11,794,000 | -22.4% | 1,654,100 | 0.0% | 0.03% | -32.5% |
| Q1 2017 | $15,201,000 | +128.0% | 1,654,100 | 0.0% | 0.04% | +66.7% |
| Q4 2016 | $6,666,000 | +5.2% | 1,654,100 | 0.0% | 0.02% | +4.3% |
| Q3 2016 | $6,335,000 | -25.5% | 1,654,100 | -16.3% | 0.02% | -32.4% |
| Q2 2016 | $8,498,000 | -7.1% | 1,976,220 | 0.0% | 0.03% | -10.5% |
| Q1 2016 | $9,150,000 | -53.8% | 1,976,220 | 0.0% | 0.04% | -58.7% |
| Q4 2015 | $19,821,000 | – | 1,976,220 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,048,642 | $3,219,000 | 0.50% |
| Virtus ETF Advisers LLC | 130,920 | $402,000 | 0.35% |
| 683 Capital Management, LLC | 600,000 | $1,842,000 | 0.16% |
| Tekla Capital Management LLC | 859,322 | $2,638,000 | 0.10% |
| DOW CHEMICAL CO /DE/ | 65,000 | $200,000 | 0.07% |
| Alambic Investment Management, L.P. | 115,834 | $356,000 | 0.05% |
| A.R.T. Advisors, LLC | 262,896 | $807,000 | 0.03% |
| Candriam S.C.A. | 520,613 | $1,598,000 | 0.03% |
| Man Group plc | 1,674,341 | $5,140,000 | 0.02% |
| Baker Brothers Advisors | 935,000 | $2,870,000 | 0.02% |